Why Intuitive Surgical Remains My Top Health Stock Pick

When financial planners talk about retirement, they often mention a number that catches most people off guard. A 65-year-old retiring in 2025 faces an average of $172,500 in medical and healthcare expenses throughout retirement. This sobering reality highlights why health stocks deserve serious consideration in any investment portfolio. For those seeking exposure to this booming sector, Intuitive Surgical (NASDAQ: ISRG) stands out as a compelling long-term investment. As a shareholder, I believe this company deserves a permanent spot in my portfolio.

The Healthcare Cost Crisis Creates Investment Opportunities

The surge in healthcare spending isn’t bad news for everyone. While patients and retirees grimace at these costs, investors recognize a powerful economic trend: money is flowing into healthcare at unprecedented rates. This spending isn’t going away—it’s accelerating as populations age and medical technology becomes more sophisticated.

Intuitive Surgical operates at the intersection of this growth trend and technological innovation. The company has established itself as the dominant force in robotic-assisted surgery, a field that promises to reshape modern medicine. Unlike commoditized healthcare segments, Intuitive commands premium pricing power and customer loyalty because its systems directly improve patient outcomes and surgeon efficiency.

The Undisputed Leader in Robotic Surgery

Intuitive Surgical has built an almost unassailable market position in robotic surgical systems. Consider the scale: the company has deployed more than 11,000 da Vinci systems across 72 countries worldwide. These machines have been used to perform over 16 million procedures since their introduction. To put this in perspective, every 11.75 seconds, a surgeon somewhere is beginning a procedure using da Vinci technology.

This installed base represents a significant competitive moat. Hospitals that have invested in da Vinci systems—which carry a premium price tag—are unlikely to switch vendors. The company has created ecosystem lock-in, much like how software platforms dominate their categories.

The beauty of Intuitive’s business model lies in its revenue streams. Only about 25% of revenue comes from selling new systems. The remaining 75% flows from servicing these machines and selling supplies—a recurring, predictable revenue stream that delivers steady cash flow quarter after quarter. This is the holy grail of healthcare investing: strong upfront sales coupled with durable aftermarket revenue.

Accelerating Growth Through Procedure Expansion

Recent financial results confirm Intuitive’s momentum. The company reported worldwide procedures up 18% year-over-year, with 532 new da Vinci systems installed globally. Total revenue grew 19% year-over-year. These aren’t just incremental gains—they reflect consistent execution in a high-growth market.

The path to future growth extends beyond simply selling more systems. Intuitive is methodically expanding the types of procedures its technology can handle. The da Vinci 5 system recently received approval for cardiac procedures, opening new surgical specialties and patient populations. Each new procedure type represents another growth vector for the installed base of existing customers.

This expansion strategy has proven remarkably effective. As surgeons gain confidence in the da Vinci platform and regulators approve new applications, hospitals justify upgrading systems and training staff in additional use cases.

AI as the Next Frontier for Medical Devices

What separates category leaders from long-term winners is their ability to innovate. Intuitive is sitting on a treasure trove of data—more than 10 million procedures have been performed using its systems. The company is now deploying artificial intelligence to unlock insights from this database that can enhance the technology itself.

The Ion system exemplifies this approach. Ion addresses a specific surgical challenge in lung biopsies known as CT-to-body divergence, where the location of a lung nodule shifts between imaging and the operating room. Intuitive’s AI-powered enhanced navigation now corrects these discrepancies in real time, improving precision and reducing procedure time.

This represents the future of medical device innovation. Companies that combine domain expertise with AI capabilities will pull further ahead of competitors. Intuitive is uniquely positioned in this regard—it understands surgery, it has unmatched procedure data, and it’s aggressively integrating AI into its platforms.

Evaluating This Health Stock for Investment

What about valuation? Intuitive Surgical isn’t a bargain-basement opportunity. The stock trades at a premium to the broader market, reflecting investor confidence in the company’s prospects. That said, the valuation is more reasonable than it was 12 months ago, suggesting a partial reset of expectations.

For investors considering entry into this health stock now, several approaches make sense. Patient investors might wait for a market pullback to build a position. Others prefer dollar-cost averaging—investing gradually over time to reduce timing risk. A third group simply enters now and commits to a long holding period, trusting that the underlying fundamentals will reward patience through market cycles.

The critical point isn’t timing the perfect entry price—it’s having the conviction to hold through volatility. Intuitive Surgical’s growth drivers (aging populations, expanding procedure approvals, AI-powered innovation) operate on multi-year and multi-decade timescales.

The Case for Long-Term Commitment

As a health stock pick, Intuitive Surgical checks every important box: dominant market position, recurring revenue streams, expanding addressable market, technological innovation, and attractive secular growth trends. The company benefits from demographic tailwinds and enjoys competitive advantages that are difficult to replicate.

Will this health stock deliver perfect returns from today’s prices? No market can guarantee that. But for investors willing to commit capital for many years—through inevitable downturns and rallies—Intuitive Surgical offers exposure to one of healthcare’s most compelling long-term trends: the automation and precision of surgical medicine. That’s a wager worth making.